Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Sidley at Solana Breakpoint 2026Sunday, November 15, 2026 - Tuesday, November 17, 2026Corporate College 2026Wednesday, October 14, 2026 - Thursday, October 15, 2026Sidley Advises InfraBridge on Sale of 50% Interest in 5.4 GW Power Portfolio to ArcLightSeptember 30, 2026Sidley Represents Electronics for Imaging in Its Combination With Agfa’s Digital Printing Solutions BusinessSeptember 28, 2026Sidley Represents Special Committee of Slate Grocery REIT in Its US$2.3 Billion Sale to Brixmor and Everview PartnersSeptember 28, 2026Sidley Represents Bluevine in Its US$340 Million Acquisition by Valley National BankSeptember 28, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory